open access

Vol 63, No 6 (2012)
Original papers
Published online: 2013-01-02
Submitted: 2013-02-15
Get Citation

Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids

Aleksandra Telega, Beata Kos-Kudła, Wanda Foltyn, Jolanta Blicharz-Dorniak, Violetta Rosiek
Endokrynologia Polska 2012;63(6):477-482.

open access

Vol 63, No 6 (2012)
Original papers
Published online: 2013-01-02
Submitted: 2013-02-15

Abstract


Introduction: Bronchopulmonary neuroendocrine tumours (BP NET) cause many diagnostic and therapeutic problems. There is an ongoing search for biochemical markers of activity of these tumours. The use of polypeptide growth factors seems potentially feasible in establishing the diagnosis, prognosis and treatment of these tumours.
Material and methods: We included 41 patients aged 25 to 78 years with histopathologically confirmed typical and atypical bronchopulmonary carcinoid tumours and 20 healthy volunteers. We assessed the levels of specific and non-specific markers of these tumours and of selected growth factors relative to TNM classification.
Results: The levels of specific markers (serotonin and its metabolite, 5-hydroxyindoleacetic acid [5HIAA]) and non-specific markers (chromogranin A [CgA]) were significantly higher in patients with atypical carcinoid tumours. The serum levels of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and VEGF receptor-1 (VEGFR-1) were significantly higher in patients with carcinoid tumours versus the control group. The levels of VEGFR-1 closely correlated with TNM classification. No such correlation could, however, be confirmed for the levels of HGF, VEGF or VEGFR-2.
Conclusions: Determination of CgA, serotonin and 5HIAA may be useful in the diagnosis of BP NET, particularly in atypical carcinoid tumours, and their levels depend on the presence of distant metastases. Determination of growth factors (VEGF and its receptor, VEGFR‑1, and HGF) may prove useful in the clinical diagnosis of these tumours, while the assessment of VEGFR‑1 expression may be helpful in tumour staging. (Endokrynol Pol 2012; 63 (6): 477–482)

Abstract


Introduction: Bronchopulmonary neuroendocrine tumours (BP NET) cause many diagnostic and therapeutic problems. There is an ongoing search for biochemical markers of activity of these tumours. The use of polypeptide growth factors seems potentially feasible in establishing the diagnosis, prognosis and treatment of these tumours.
Material and methods: We included 41 patients aged 25 to 78 years with histopathologically confirmed typical and atypical bronchopulmonary carcinoid tumours and 20 healthy volunteers. We assessed the levels of specific and non-specific markers of these tumours and of selected growth factors relative to TNM classification.
Results: The levels of specific markers (serotonin and its metabolite, 5-hydroxyindoleacetic acid [5HIAA]) and non-specific markers (chromogranin A [CgA]) were significantly higher in patients with atypical carcinoid tumours. The serum levels of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and VEGF receptor-1 (VEGFR-1) were significantly higher in patients with carcinoid tumours versus the control group. The levels of VEGFR-1 closely correlated with TNM classification. No such correlation could, however, be confirmed for the levels of HGF, VEGF or VEGFR-2.
Conclusions: Determination of CgA, serotonin and 5HIAA may be useful in the diagnosis of BP NET, particularly in atypical carcinoid tumours, and their levels depend on the presence of distant metastases. Determination of growth factors (VEGF and its receptor, VEGFR‑1, and HGF) may prove useful in the clinical diagnosis of these tumours, while the assessment of VEGFR‑1 expression may be helpful in tumour staging. (Endokrynol Pol 2012; 63 (6): 477–482)
Get Citation

Keywords

chromogranin A; serotonin; 5HIAA; growth factors; VEGF; VEGFR; HGF; typical and atypical lung carcinoid tumour

About this article
Title

Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids

Journal

Endokrynologia Polska

Issue

Vol 63, No 6 (2012)

Pages

477-482

Published online

2013-01-02

Bibliographic record

Endokrynologia Polska 2012;63(6):477-482.

Keywords

chromogranin A
serotonin
5HIAA
growth factors
VEGF
VEGFR
HGF
typical and atypical lung carcinoid tumour

Authors

Aleksandra Telega
Beata Kos-Kudła
Wanda Foltyn
Jolanta Blicharz-Dorniak
Violetta Rosiek

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl